factual

NADS Oligonucleotide Business Grew From Tiny Origins

Agilent's Nucleic Acid Solutions Department (NADS) makes oligonucleotides used to stabilize RNA during production of RNA-based drugs and vaccines, including COVID-19 vaccines; it began as a tiny unit formed in 2006 from in-house RNA synthesis know-how and the SynPro acquisition, and it became the clear leader in the niche.

factualpending

Speaker

Marc

Evidence Quote

“It was formed in 2006 by merging some technology Agilent already had in-house, which was around knowledge on RNA molecule synthesis, with a business they acquired called SynPro.”

Source

Agilent: Back To The Lab— Business Breakdowns
Created: 11/12/2026, 11:55:35 AM

Your notes

Loading notes...